Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Open Access
- 23 March 2017
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 18, 56-61
- https://doi.org/10.1016/j.ebiom.2017.03.029
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanomaBritish Journal of Dermatology, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaThe New England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibThe New England Journal of Medicine, 2015
- A Preoperative Neutrophil to Lymphocyte Ratio of 3 Predicts Disease-Free Survival After Curative Elective Colorectal Cancer SurgeryAnnals of Surgery, 2014
- Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancerGynecologic Oncology, 2014
- Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival After Hepatectomy for Hepatocellular CarcinomaAnnals of Surgery, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal TumorAnnals of Surgical Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009